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Cancer is one of the major threats worldwide. Treatments with 
chemotherapeutic drugs affect both cancerous and healthy cells, leading to severe 
side effects. Nanoparticles (NPs) not only can protect the drugs from degradation, 
but also localize the drug to tumor tissues by enhanced permeability and retention 
(EPR) effect. In this project, buforin lib (Bllb) and Luff in P I are chosen for 
incorporation into chitosan (CS)-based nanocarrier for developing into an efficient 
anti-cancer agent. 
Since Luffin PI, which is claimed to be a ribosome-inactivating peptide (RIP), 
does not have any 3D structural information, we have solved its solution structure 
by NMR, which is useful for us to design Luffin P I incorporated CS particles. 
Nevertheless, from the solution structure of Luffin PI, no conserved RIP active sites 
could be found. Additionally, we proved that Luffin P I does not show any 
N-glycosidase activity. As there was a discrepancy between our data and the 
previous reported data, we did not proceed to use it for nanoparticle construction. 
On the other hand, Bllb was successfully incorporated into positively charged 
(+ve) and negatively charged (-ve) CS NPs to generate +ve CS-DTSSP Bllb NPs 
and -ve CS-Bllb NPs respectively. The toxicity, encapsulation efficiency and loading 
capacity, and in vitro releasing rate of -ve CS-B!lb NPs were all higher than those of 
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+ve CS-DTSSP Bllb NPs. As a result, -ve CS-Blib NPs may be further developed to 







(Bl lb)和Luf f in PI分別加入以殼聚酷（CS)爲基礎的納米載體，希望可發展 
成有效的抗癌藥物。 
Luffin PI是一種核糖體失活肽（RIP)，由於其三維結構還未被解讀’所以 





的穀聚醣粒子結合’產生+ve CS-DTSSP Bllb NPs和-ve CS-BIIb NPs兩種結合體。 
實驗証明-ve CS-BIIb NPs的毒性、包封率、載藥量及釋放率均高於+ve CS-DTSSP 
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Chapter 1 一 Introduction 
1.1 Introduction to nanoparticle 
Nanoparticles (NPs) are usually with diameter between 1 nm and 1000 nm 
(Laroui et al., 2011; Nagpal et al., 2010) and commonly consist of lipids or polymers 
to form liposome and polymeric micelle respectively (Davis et al., 2008). Materials 
which are non-toxic, biodegradable, biocompatible and low-immunogenic are 
usually chosen for constructing NPs (Minelli et al., 2010). For examples, silica, 
carbon and chitosan derivate called alginate—chitosan—poly(lac1:ic-co-glycolic acid) 
(PLGA) are frequently used for making nanocarrier (Hocine et al., 2010; Huang et al” 
2011; Zheng et al., 2004). 
Nowadays, NPs have been widely chosen for biomedical applications such as 
drug carriers for treating cancers and diseases like diabetes (Makhlof et al., 2010; 
Schluep et al., 2009), delivering DNA or RNA in gene therapy (Hood et al., 2002; 
Toub et al., 2006) in vivo bioimaging (Yu et al., 2008) and tissue repairing or 
engineering (Serrano et al., 2007). 
There are several advantages using NPs as drug carriers: Firstly, some NPs can 
increase the water solubility of certain drugs. For instance, an anti-cancer drug, 
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camptothecin, is not water soluble, but its water solubility increases after loaded in 
poly-£-caprolactone nanocarrier (Cirpanii et al., 2010). 
Secondly, degree of drug degradation, especially protein drugs, during blood 
circulation will be lowered after the drugs are trapped in NPs. One of the 
successful examples is that the stability of insulin is largely increased after binding 
with arginine end-functionalized poly(L-lysine) dendrigrafts carrier (Sideratou et al., 
2010). 
Thirdly, some NP platforms are capable of surface bio-conjunction to 
antibodies for particular cells or tissues, which can provide lesser side effects on 
healthy cells or tissues. For example, anti-CD4 monoclonal antibody has been 
conjugated on magnetic poly(glycidyl methacrylate) particle to target HIV-infected 
cells (Pimphaetal., 2011). 
Fourthly, NPs sometimes can allow the drugs to have longer blood circulation 
time. Without NPs, drugs will be removed by two ways: 1. Removed by immune 
cells like macrophage if drug is protein in nature. 2. Excreted as a waste product 
from kidneys when drug is small enough to pass through the glomerular capillary 
wall (the threshold for pass elimination by kidney is estimated at 10 nm diameter) 
(Venturoli & Rippe, 2005). For example, 5-fluorouracil (5-FU) is a small chemical 
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anti-cancer drug with short elimination half-life in BALB/c nude mice (5 minutes). 
But once 5-FU has loaded into mixture of poly(-benzyl-L-glutamate) (PBLG) and 
poly(ethylene glycol) (PEG) to form 5-FU loaded PEG-PBLG NPs, the elimination 
half-life of 5-FU loaded PEG-PBLG NPs increase greatly to 33.3 hours (Li et al., 2008). 
Finally, NPs allow drug to be released in a controlled manner. 
Doxorubicin-incorporated deoxycholic acid-conjugated dextran nanoparticle 
(DOX-incorporated DexDA NP) is a good example illustrating how the release of 
DOX from NPs can be controlled. DOX is an anti-cancer drug which causes serious 
side effects, such as cardiac toxicity and hematological disorders. After DOX is 
incorporated into DexDA NPs, the initial release of DOX is fairly slow and 
continuously releasing over 1 week. This allows the drug to be released slowly 
before reaching cancer tissue and kill cancer cells after the NPs get around the 
cancer tissue (Jeong et al., 2011). 
Overall, using NPs as drug carrier stands a favored position to attract us to 
develop a new NP carrier for peptide drugs delivery and table 1 shows some 
therapeutic NP examples approved by the U.S. Food and Drug Administration (FDA) 
or under clinical/preclinical trials (Davis et al" 2008). 
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Platform Stage of development Examples 
Liposomes Approved DaunoXome, Doxil 
Albumin-based particles Approved Abraxane 
PEGylated protein Approved Oncospar, PEG-lntron, 
PEGASYS, Neulasta 
Biodegradable Clinical trials Doxorubicin Transdrug 
polymer-drug 
composites 
Polymeric micelles Clinical trials Genexol-PM, SP1049C, 
NK911, NK012, NK105, 
NC-6004 
Polymer-drug Clinical trials XYOTAX (CT-2103), 







Dendrimers Preclinical Polyamidoamine 
(PAMAM) 
Table 1 Various therapeutic NPs made by different platforms are approved by FDA 
or under clinical/preclinical trials (Davis et al., 2008). 
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1.2 How to treat solid cancers using nanoparticle drugs (IMP drugs) 
Efficacy of NP drugs varies depending on the targeted diseases and tissues. 
For treating solid tumors, particle size and surface characteristics are the two 
primary factors affecting the drug efficacy (Allen & Cull is, 2004). 
The optimal size for NP drug to treat solid tumors through intravenous (i.v.) 
injection is with diameter between 10 nm and around 200 nm. NPs with size less 
than 10 nm will be eliminated by renal clearance as mentioned earlier while NPs 
larger than 200 nm with no targeting moieties, like antibody, can hardly accumulate 
around tumor tissues (Bisht & Maitra, 2009; Tomme et al., 2008). Different from 
the tight blood vessels found in normal tissues, angiogenic blood vessels in cancer 
tissues have large gaps or holes with size from 600 nm to 800 nm between adjacent 
endothelial cells (Edens et al., 2002; Wang et al., 2008). This immature and 
defective vascular structure allows macromolecules leaking from blood to 
accumulate in the interstitial spaces of cancer tissues. This phenomenon is known 
as "enhanced permeability and retention (EPR) effect" (Jain, 1987; Matsumura & 
Maeda, 1986) (Fig. 1.1). Since macromolecules will selectively accumulate in 
tumor tissue, this is also one of the "passive targeting" mechanisms. Although the 
gaps found in vascular around tumor tissues are as large as 600 nm, particles of size 
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less than 200 nm with hydrophilic surfaces are shown to accumulate most around 
the tissues (Bisht & Maitra, 2009; Tom me et al., 2008). 
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Fig. 1.1 Schematic diagram of NP drug accumulation in tumor tissue but not 
normal tissue by EPR effect. Blood vessels in normal tissue are lined by tight 
endothelial cells, which can prevent NP drugs from entering. However, the vessels 
in tumor tissue are leaky and hyperpermeable, which allows NP drugs with size less 
than 150 nm to accumulate in the tumor interstitial space. 
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After building up NP drugs around tumor cells by EPR effect, the drug efficacy 
will largely depend on whether the NPs can be internalized into cancer cells. For 
NPs without targeting moiety, it is shown that nonphagocytic eukaryotic cells can 
internalize particles easily if the size is smaller than 1 \im (Lacoeuille et al.； 2007). 
Due to the EPR effect, particles accumulated in tumor tissues are always smaller 
than 1 |im, which help to deliver the drugs inside solid cancer cells by internalization. 
On the other hand, NPs internalization will be easily achieved when the targeting 
moiety like monoclonal antibody (mAb) or single chain variable fragment (scFv) is 
attached on the surface of NPs. With mAb, receptor-mediated endocytosis should 
occur frequently after NPs get around tumor tissues, which help to increase the 
intracellular drug concentration (Ferrari, 2005; Thierry, 2009). 
Surface charge of NPs also affects the drug disposition by i.v. or intratumoral 
injection (Koreeda, et al., 1998). Positively charged NPs are found to be remained 
in tumor tissue after intratumoral injection as cationic NPs can interact with the 
negative charges ofglycocalyx such as glycoproteins on cancer cell surface as well as 
with constituents in interstitial fluid like proteoglycans (Saikawa, et al., 1998). On 
the other hand, anionic and neutral NPs can move through tumor tissues. As a 
result, depending on the injection methods, different surface charges of NPs should 
be chosen for better NPs distribution. For example, positively charged NPs should 
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be used when intratumoral injection is performed because cationic NPs may 
interact with negatively charged surface of cancer cells and hence the localization of 
cationic NPs will mainly be restricted in tumor tissue. Conversely, when i.v. 
injection is performed, neutral or negatively charged NPs should be chosen as it can 
pass through the whole tumor tissue and reach the interior part of the tissue. If 
cationic NPs are used in this case, the NPs might probably interact with the exterior 
part of the tissue only (Koreeda, et al., 1998). 
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1.3 What is Chitosan (CS)? 
Chitosan is a linear polysaccharide with amino and hydroxy I groups, hence it is 
a hydrophilic molecule (Fig. 1.2). It is easily obtained by deacetylation of chit in by 
simply boiling chitin with NaOH and potassium permanganate (van der Lubben et al., 
2001). Since chitin can be abundantly found in exoskeletons of crustaceans like 
crabs and shrimps, the production costs of chitosan is relatively low. 
1 0 
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Fig. 1.2 Structures of (A.) chitin and (B.) chitosan. After deacetylation process' 
acetyl groups of chitin are removed and amino groups of chitosan are exposed. 
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Chitosan is biodegradable and biocompatible material for nanoparticle 
generation. Chitosan is digested by chitinase which is secreted by intestinal 
microorganism and can be found in lysozymes (Aiba, 1993). Its blood compatibility 
has also been shown as good (Lee et al., 1995). As a result, chitosan is a good 
candidate to be used as drug carrier for oral administration or i.v. 
injection. Additionally, chitosan has been approved by FDA, which increasingly 
attracts the pharmaceutical and food developers on applications of chitosan 
(Dodane, 1998). 
The charge on chitosan is depending on the solution pH value. The pKa of 
the amine groups on chitosan is approximately 6.5, which are protonated in acidic 
solutions, including acetic, tartaric and citric acid, when the pH value is less than 6. 
In this case, chitosan is positively charged and water soluble. Conversely, if the 
pH is higher than 7, the amino groups are deprontonated and chitosan becomes 
neutral and water insoluble. In order to increase the water solubility of chitosan in 
neutral or basic solution, amine groups of chitosan are chemically modified to form 
trimethyl chitosan derivatives, which are still soluble at pH above 6.5 (Mourya & 
Inamdar, 2009). Moreover, unmodified chitosan has recently been found to be 
water soluble and still carry positive charges at pH 7.4 in the presence of 0.1 M 
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sodium bicarbonate (NaHCOs). This can definitively help chitosan to be developed 
as drug carrier (Zhong et al., 2011). 
Since chitosan is cheap and an approved biomaterial by FDA, chitosan and its 
derivatives have gained attention as drug carriers. For example, chitosan has been 
suggested to be a gene delivery vector as its toxicity is much lower than 
poly-L-lysine； polyethylenimine and Lipofectamine^'^ (Erbacher et al., 1998; 
MacLaughlin et al., 1998; Mao et al” 2001). KNOB (C-terminal globular domain of 
fiber protein) conjugated chitosan and alginate-chitosan NPs have been developed 
to have high transfection efficiency in HeLa cells and 293T cells respectively (Mao et 
al., 2001; Yang etal., 2010). 
Apart from delivering DNA, insulin is successfully trapped by chitosan 
derivative called chitosna-dextran sulphate. These insulin-trapped NPs have been 
reported to lower the blood glucose level in a diabetic rat model (Lin et al., 2007). 
Furthermore, a chitosan derivative, carboxymethyl-hexanoyI chitosan (CHC), with 
very high water solubility in neutral condition is developed to encapsulate a 
non-steroidal anti-inflammatory drug, ibuprofen (Liu et al., 2010). 
After all, chitosan is an attractive biomaterial for NPs generation as it is easy to 
be modified, low immunogenic, biodegradable and biocompatible. 
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1.4 Possible peptide candidates to be trapped 
Peptides have great potential for treating diseases because they generally 
have higher cell targeting specificity than chemical drug and can be produced by 
recombinant protein expression in E. coli to lower the production cost. 
Unfortunately, peptides have its limitations, such as quick renal clearance. In 
order to increase the efficacy of peptide drugs and prolong its plasma half-life, 
chitosan (CS) is developed as peptide drug carrier in this project. Since the size of 
NP drugs for treating cancers is less than 200 nm, small peptide toxins should be 
chosen to be trapped in CS particles. In this project, two small peptide toxins 
named Luffin P I and Buforin Mb (Bllb) are selected to be trapped in CS particles. 
1.4.1 Luffin P I - Ribosome inactivating peptide 
Ribosome inactivating peptides (RIP) have similar activity as ribosome-
inactivating proteins which are N-glycosidases that cleave N-glycosylic bond and 
hence remove a specific adenine residue at a highly conserved a-sarcin/ricin loop 
(SRL) of 23S and 28S rRNA of ribosome (Endo et al., 1988; Stirpe et al., 2006; Wool 
et al., 1992). This irreversible action decreases the affinity of ribosome to bind to 
elongation factors which catalyze the translocation of the elongated peptidyl-tRNA 
from A site to P site. Therefore, ribosome becomes inactivated after depurination 
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by ribosome-inactivating proteins and protein synthesis is arrested (Brigotti et al” 
1989; Montanaro et al., 1975; Motto et al., 2004). 
Luff in PI, which is extracted from the seeds of Luffa cylindrical, is the smallest 
RIP with molecular weight of around 5.4 kDa with amino sequence: 
GSPRTEYEACRVRCQVAEHGVERQRRCQQVCEKRLREREGRRE. Interestingly, from the 
primary amino acid sequence of Luff in PI, we cannot find the conserved catalytic 
residues (in the case of trichosanthin, a plant RIP with molecular weight of 36.6 kDA, 
the catalytic residues are Y70, Y l l l , E160, R163 and W192). However, Luffin P I 
displays a highly potent inhibitory activity on protein synthesis in the cell-free rabbit 
reticulocyte lysate with IC50 = 0.88 nM while that of trichosanthin, a strong 
ribosome inactivating protein, is 0.0312 nM (Li et al., 2003). Owing to its small 
molecular size and high protein synthesis inhibitory potency, Luffin P I has been 
successfully developed as immunotoxin by linking it to human interleukin-2 to 
target activated T cells (Wang et al., 2010). 
Overall, Luffin P I is a suitable candidate to be trapped in CS particles due to 
its small size and high toxicity. 
1.4.2 Buforin lib (Bllb) - Antimicrobial peptide 
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Antimicrobial peptides (AMPs) are positively charged and have the ability to 
kill gram positive and/or negative bacteria. The mechanism of most people 
accepted on AMPs action is the positively charged AMPs interacting directly with 
the negatively charged membranes of bacterial cells. This will increase the 
membrane permeability which results in cell death (Zaiou, 2007). Nevertheless, 
after interacting with the negatively charged membranes of bacterial cells, Buforin 
lib (Bllb), which is derived from histone H2A, gets into cytoplasm of the cells 
without making any pores on the membranes and this is believed to inhibit cellular 
functions by binding it to DNA and RNA in cytoplasm and nucleus (Park et al., 1998). 
Bllb displays anti-cancer activity towards 62 cancer cell lines. This anti-cancer 
activity is shown firstly getting into the cells by interacting with the negatively 
charged gangliosides on the cell surface without damaging the membrane and 
secondly accumulating in cytoplasm and mainly nucleus. Finally, the cells undergo 
mitochondria-dependent apoptosis. Interestingly, Bllb is not cytotoxic to normal 
proliferating cells, such as human fibroblasts, and peripheral blood lymphocytes 
(Lee et al., 2008). 
Bllb is a 21-amino-acid peptide (sequence: RAGLQFPVGRLLRRLLRRLLR) 
and has a structure similar to other a-helical AMPs. From structure-function study, 
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it is shown that the a-helical content and residues at C-terminal of Bllb are critical 
factors to determine its toxicity: the lower the overall a-helical content and the 
more deleted residues at C-terminal, the lower the toxicity (Park et al., 2000; Yi et 
al., 1996). In addition, specific interaction between Bllb and DNA was illustrated 
and the toxicity also decreases when its DNA affinity falls (Uyterhoeven et al., 
2008). 
After all, Bllb is another possible candidate to be trapped because it has high 
cytotoxicty towards tumors but not normal cells. 
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1.5 Aims of study 
The first aim of this study is to solve the structure of Luffin PI. By knowing 
the structure of Luffin PI, it can help us to understand how it exerts the toxicity. 
This can help us to find a better method to incorporate Luffin P I into CS particles 
without affecting its activity and to shorten its length for smaller CS-Luffin P I 
particles generation. 
The second aim is to develop CS as a peptide carrier for treating solid tumors. 
Since peptides are easily lost by renal clearance because of its small molecular size, 
CS-peptide NPs can definitely increase the circulation time by protecting peptide 
from being removed by macrophages and kidneys and thus increase the peptide 
drug efficacy. 
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Chapter 2 - Materials and methods 
2.1 Materials 
HeLa and J774A.1 cell line were maintained in Dulbecco's Modified Eagle's 
Medium (DMEM) containing 10% fetal bovine serum at 37�C in 5% CO2. Buforin lib 
(sequence: RAGLQFPVGRLLRRLLRRLLR, purity: >90%) was purchased from GenScript. 
Cy5 and N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (CDI) were 
purchased from International Laboratory USA. The gene of Luffin P I was cloned 
into pHis-SUMO vector for expression of SUMO-tagged Luffin P I in Escherichia coli. 
2.2 Methods 
2.2.1 Construction and expression of Luffin PI 
The DNA segment coding for the Luffin P I peptides was generated by 
overlapping PCR. Primer 1 (5' ggaattccatatgggctctccacggacc 3') was overlapped 
with primer 2 (5' gctccgccacttggcatcgaactcgacacgcctcatactcggtccgtggagagcc 3') to 
generate fragment 1. Then fragment 1 was overlapped with primer 3 (5' 
ctcacagacctgttgacacctgcgttgccgctccacccctgctccgccacttggc 3') to generate fragment 2. 
Finally, primer 4 (5' cgggatccttactcccgccggccctctcgctccctcagccgcttctcacagacctgttgaca 
cc 3') was overlapped with fragment 2 to generate the gene coding for Luffin PI. 
The gene was cloned into the pHis-SUMO vector using the Age I and BamHI 
restriction sites. The expression vector is a modified SUMO plasmid with a SUMO 
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protease-recognition site inserted between SUMO-tag and the protein of interest. 
The clones were sequenced to ensure that it encodes a Histidine affinity purification 
tag, followed by the sequence representing the SUMO and Luff in PI. Luffin P I was 
expressed in the Escherichia coli strain T7 Express I" (NEB #C3016, Genotype: 
MiniF /oc/'^ lCam )^ /fhuA2 lacZ::T7 genel [Ion] ompT gal sulAll 
R(mcr-73::miniTnlO-Tet^)2 Idem] R(zgb-210::Tnl0-'\e\^} endAl 
A(mcrC-mrr)114::ISl0). The recombinant protein was purified with a Ni-NTA 
affinity column (GE Healthcare). The SUMO-fusion protein was eluted with 
increasing concentration of imidazole and the SUMO-tag was removed by overnight 
SUMO-protease digestion at 4 � C Then Luffin P I was recovered and further purified 
by a Ni-NTA affinity column and Superdex 75 (GE Healthcare) gel filtration column 
on the AKTA Fast Protein Liquid Chromatography system (GE Healthcare). The 
protein purity was checked by 15% SDS-PAGE. Uniformly 15N-labeled 
recombinant Luffin P I was over-expressed using minimal medium containing 1 g/l 
99% 15NH4CI as the sole nitrogen source. The final NMR sample was prepared in a 
solution containing 20 mM sodium phosphate, 150 mM NaCI, pH 6.8 and 1 x 
protease inhibitor cocktail (Roche) in 90% H20/10% D2O with volume of 0.5 ml and 
protein concentration of about 0.7 mM. 
2.2.2 Circular dichroism spectroscopy 
2 0 
Luffin P I was dissolved in 20 mM phosphate buffer, 150 mM NaCI, pH 6.8 
(0.26 mg/ml). CD spectra were measured over the range of 190-250 nm in a 
cuvette of path length of 1 mm by using a JASCO J-720 spectrometer (Easton； MD). 
All spectra were measured at 25 °C with a scan speed of 50 nm/min, response time 
of 1 s. Each spectrum was an average of three accumulations, and data were 
collected at 0.1-nm intervals. After subtraction of the appropriate blank buffer 
background curve, quantitative estimations of the secondary structure content 
were made by using the CDSSTR, SELC0N3, and CONTINLL programs included in the 
CDPro software package (Sreerama et al., 1999). 
2.2.3 Static light scattering 
Luffin P I was loaded onto a Superdex 200 column (GE Healthcare) which is 
controlled by an AKTA explorer chromatography system (GE Healthcare), 
equilibrated with SEC buffer (20 mM sodium phosphate (pH 6.8) and 150 mM NaCI), 
and coupled to a miniDAWN triangle light scattering detector (Wyatt Technology 
Corporation, Santa Barbara, CA) connected to an Optilab DSP interferometric 
refractometer (Wyatt Technology Corporation). Sample volume of 100 jil was 
injected at a flow rate of 0.5 ml/min. The laser scattering (687 nm) and the 
refractive index (690 nm) of the respective protein solutions were recorded. Data 
analysis was carried out using Wyatt ASTRA software and molecular mass was 
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calculated using the Debye fit method. 
2.2.4 In vitro N-glycosidase assay 
Protein samples with different concentration were mixed with rabbit 
reticulocyte lysate in the presence of creatine kinase, creatine phosphate, hemine, 
KCI/MgCb and DEPC-H2O. The mixtures were incubated at 30°C for 30 minutes, 
and the reaction was terminated by adding 25 pil of 10% SDS. After incubation, the 
total RNA of the mixtures was extracted using Trizol by standard protocol. Then 
the purified RNA was split into two aliquots. Aniline was added in to one of the 
aliquots while DEPC-H2O was added into another one with 60�C incubation for 3 
minutes. Finally, the RNA samples were loaded into 1% agarose gel stained by 
ethidium bromide. 
2.2.5 Preparation of Chitosan (CS) NPs 
2.2.5.1 Preparation of positive (+ve) CS NPs 
CS solution for +ve CS NPs generation was prepared by dissolving CS powder 
into 3% acetic acid and sterilized by passing through 0.2 \xm filter. TPP solution 
was prepared by dissolving TPP powder into distilled water and sterilized by passing 
through 0.2 |im filter. The effects of fixed volume but different concentrations of 
TPP and CS solution on +ve CS NPs were examined (Table 2 in Chapter 4). 5 ml of 
CS solution was added into 2 ml of TPP solution drop by drop with stirring at room 
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temperature. After 1 hour of stirring, +ve CS NPs were washed by 0.1 M NaHCOs 
solution or PBS. 
2.2.5.2 Preparation of negative (-ve) CS NPs 
1% CS solution for -ve CS NPs generation was prepared by dissolving CS 
powder into 2% HCI and sterilized by passing through 0.2 |im filter. Carboxylic acid 
was dissolved in 1.5 ml distilled water and then its pH was adjusted to 6.5 by 2 M 
NaOH. Then water-soluble N-(3-dimethylaminopropy!)-N'-ethylcarbodiimide 
hydrochloride (CDI) was added into carboxylic acid solution. This mixture was stirred 
at 4 °C for 30 min followed by adding 1 ml of 1% CS solution to the mixture drop by 
drop. After 24 hours of stirring at 4 -ve CS NPs generated in this mixture was 
washed by PBS. The data of the synthesis are summarized in Table 3 in Chapter 5. 
2.2.5.3 Preparation of buforin lib (Bllb) incorporated NPs 
To incorporate Bllb into +ve CS NPs to generate +ve CS-DTSSP Bllb NPs, +ve CS 
NPs was firstly generated. Then, 1 mg of Bllb powder was dissolved in 1 ml of 
18.45 mg/ml +ve CS NPs. A chemical cross-linker, 
(3,3'-dithiobis[sulfosuccinimidyl-propionate] (DTSSP), was dissolved into distilled 
water. Finally, 200 ui of 3.28 piM DTSSP was added into the mixture of +ve CS NPs 
and Bllb drop by drop with stirring for 1 hour, for generating +ve CS NPs linked to 
Bllb by DTSSP (+ve CS-DTSSP-Bllb NPs). +ve CS-DTSSP Bllb NPs was washed by PBS. 
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To incorporate Bllb into -ve CS NPs to generate -ve CS-BIIb NPs, 1 mg of Bllb 
powder was dissolved into 1% CS solution and added to the mixture of carboxylic 
acid and CDI. After 24 hours of stirring at room temperature, -ve CS-BIIb NPs 
generated in this mixture was washed by PBS. 
2.2.5.4 Preparation ofCyS incorporated NPs (-ve CS-Cy5-Bllb NPs) 
The method is similar to that of -ve CS-BIIb NPs generation. The only 
difference is 5 mg Cy5 but not 1 mg Bllb was dissolved in 1% CS solution. 
2.2.6 Characterization of CS NPs 
The morphologies and sizes of all NPs were examined and measured under an 
FEX XL-F40 scanning electron microscope (SEM) in CUHK and JSM-6700F SEM 
HKUST. 
Zeta potential (surface charge) of NPs was measured at least in triplicate using 
DelsaTM Nano C (Beckman Coulter, CA). All NPs were suspended in PBS at pH 7.4. 
2.2.7 Buforin lib (Bllb) encapsulation efficiency and loading capacity 
To determine the encapsulation efficiency and loading capacity, the NPs were 
centrifuged at 14, 000 rpm and 4 � C for 10 minutes. The amount of free Bllb was 
determined in the supernatant by UV spectrophotometry (Beckman Coulter DU800) 
at 205 nm. Bllb encapsulation efficiency and loading capacity were calculated as 
indicated below: 
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(Total amount of Bllb - Free amount of Bllb) 
Encapsulation efficiency (o/o) = Total amount of Bllb 乂 • 
、 (Total amount of Bllb - Free amount of Bllb) … 
Loading capacity (o/o) = Nanoparticle weight 乂 • 
2.2.8 In vitro release study 
5 mg of the NPs was suspended in 1 ml of PBS at pH 4, 7.4 or 10. It was 
placed in a dialysis bag with MWCO 10,000 and put into 10 ml of PBS at pH 4, 7.4 or 
10. The whole system was kept at 37 °C. At predetermined intervals, 3 ml of 
outer phase PBS was taken out and measured by UV spectrophotometry at 205 nm. 
The volume of the outer phase PBS was maintained constant by replacing 3 ml of 
fresh PBS. 
2.2.9 Confocal Microscopy 
1 X 10^ M HeLa and J774A.1 cells were seeded onto glass cover slips and 
cultured overnight, -ve CS-Cy5-Bllb NPs was washed extensively by PBS to ensure 
all free Cy5 was removed. The cells were than incubated with 10 mg/ml -ve 
CS-Cy5-Bllb NPs at 37�C incubator for 4 hours. Excess -ve CS-Cy5-Bllb NPs was 
washed away by PBS and the cells were fixed in cold 4% paraformaldehyde in PBS 
for 10 min:jtG£. The cover slips were washed by PBS again and mounted on glass 
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slide using Fluorescent mounting medium (Dako). The cells were observed under 
SP5 confocal microscopy to capture the images. 
2.2.10 Cytotoxicty assay 
100 \i\ culture medium of 1 x icf cells were seeded into the wells of 96-well 
plate and cultured overnight. The NPs suspended in culture medium were 
incubated with the cells for 72 hours at 37 °C incubator. After 72 hours, 50 \i\ of 5 
mg/ml MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) was 
added into the wells and the cultures were incubated for 3 hours until purple color 
precipitate was developed. 100 of DMSO was added to dissolve the precipitate. 
The data was recorded by micro-plate reader at 595 nm. 
2.2.11 Statistical analysis 
All the data were analyzed by Prism 5 (GraphPad Software, Inc., San Diego, CA) 
and expressed as mean 士 SEM. One tailed paired t test was used to compare the 
zeta potential of different samples. Differences were considered as statistically 
significant when P < 0.05. 
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Chapter 3 一 Cloning, expression, purification and 
structural characterization of Luffin P I 
3.1 Introduction 
Luffin P I is the smallest RIP with a molecular weight around 5.4 kDa. It 
displays a cell-free translation-inhibiting potency (IC50 = 0.88 nM), which is similar to 
types I and III RIPs but higher than type II RIPs (Au et al” 2000). Another group of 
investigators reported hlL2-Luffin P I immunotoxin exhibits potent inhibitory activity 
on T-cell proliferation in vitro and significantly prolongs the survival of 
MHC-mismatched skin and renal allografts in vivo (Wang et al., 2010). 
There are also some small RIPs other than Luffin P I with molecular weight of 
about or less than 10 kDa, such as bitter gourd seeds designated c-momorcharin (Pu, 
Lu, W. Y. Liu, & Jin, 1996), sponge gourd seeds designated Luffin-S2 (Gao et al., 1994) 
and fresh brown pumpkin seeds designated a-moschin and P-moschin (Ng et al., 
2002). However, there is no 3D structural information for these small RIPs. The 
amino acid compositions of these small RIPs mainly consist of arginine and 
glutamate, which is different from the amino acid sequences of those well-known 
RIPs, such as TCS and ricin. As a result, these small RIPs may also be called 
arginine/glutamate-rich polypeptide (AGRP). 
Since 3D structure of Luffin P I is useful for us to design Luffin P I incorporated 
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CS particles (CS-Luffin P I particles) and we cannot find its related structures from 
other small RIPs, I have carried out the cloning, expression and purification of Luffin 
P I for the solution structure analysis of Luffin P I by NMR spectroscopy. Then, I 
would also design experiments to generate CS-Luffin P I particles. 
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3.2 Results 
3.2.1 Construction of Luffin P I plasmid 
DNA segment of Luffin P I was generated by overlapping PGR with the 4 
primers mentioned in Chapter 2. Then this gene was successfully cloned into 
pHis-SUMO expression vector - a vector with a SUMO protease-reorganization site 
inserted between SUMO-tag and the protein of interested. The clone was 
sequenced to ensure that it encodes a Histidine affinity purification tag, followed by 
the sequence encoding the SUMO-tag and Luffin PI. 
3.2.2 Expression and purification of Luffin P I 
After expressing His-SUMO-Luffin P I in E. coli strain T7 Express for 6 h at 25 
an extra band was found at 20 kDa when compared with that without induction 
(Fig. 3.1). The cells after expression were collected and sonicated. 
His-SUMO-Luffin P I was eluted by 300 mM imidazole after passing the supernatant 
through Ni-NTA affinity column. Then SUMO-protease was added in the elution 
and incubated overnight at 4 °C to separate Luffin P I from His-SUMO. Finally, 
Luffin P I was obtained after purified by Ni-NTA affinity column again and Superdex 
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Fig. 3.1 Expression and purification of Luffin PI. His-SUMO-Luffin P I was 
expressed in 17 Express competent E. coli strain and a band at 20 kDa was found. 
After sonicating the cell pellet, His-SUMO-Luffin P I was purified by passing the 
supernatant through Ni-NTA affinity column. After SUMO-protease digestion, 
Luffin P I was separated from His-SUMO and SUMO-protease by passing through 
Ni-NTA affinity column again and Superdex 75 gel filtration column. 
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3.2.3 Molecular weight and secondary structure determination of Luffin P I 
Static light scattering (SLS) experiments were performed in combination with 
size exclusion chromatography to characterize the molecular weight of Luffin P I in 
20 mM sodium phosphate, 150 mM NaCI (Fig. 3.2A). The data showed that Luffin 
P I is monodisperse with a molecular weight of about 5.4 kDa, suggesting that it 
has a monomeric nature in hydrophilic condition. Luffin P I global secondary 
structure was evaluated using far-UV CD spectroscopy. Deconvolution analysis 
revealed that the polypeptide is exclusively helical and the structure content of 
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Fig. 3.2 Luffin P I is monomeric and helical. (A) Static light scattering analysis of 
Luffin P I is represented by a molecular mass versus volume plot overlaid with gel 
filtration elution profile. The calculated molecular mass shows that Luffin P I is a 
monomer in solution. (B) Circular dichroism spectrum of Luffin P I in 20 mM PBS, 
150 mM NaCI, pH 6.8, exhibits double minima at 208 and 222 nm, which represents 
the characteristic of a-helical structure. 
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3.2.4 3D solution structure of Luffin P I 
After finishing characterization experiments mentioned above, both 
iSiM-labelled and unlabelled Luffin P I protein were purified and given to my labmate, 
Dr. Yinhua Yang, to solve its solution structure by homonuclear and heteronuclear 
NMR. As shown in Fig. 3.3A and B, the structure of Luffin P I is relatively rigid with 
two nearly anti-parallel a-helices spanning residues 5-17 and 22-39, that are bound 
by a short turn of four residues and stabilized by two disulfide bonds involving 
CyslO/Cys31 and Cysl4/Cys27. These two disulfide bonds are located adjacent to 
one another, on the same side of each helix with the cysteines each separated by 
one helical turn. Four residues are disordered at the N-terminus of the Luffin PI, 
and four at the C-terminus. 
Luffin P I also has vast number of exposed residues, most of them bearing 
charged groups. The electrostatic surface model lacks an extensive hydrophobic 
core and most of the charged residues are facing the outer surface of the 
polypeptide (Fig. 3.3C and D). The surfaces of the core domain are dominated by 
charged groups. The unstructured head is positive and the unstructured tail is 
charged with one arginine and one glutamate residues, whereas the structured part 
has a positive and a negative face as can be seen in Fig. 3.3C and D. The main 
cluster of positive charges is composed of residues Argi l , Argl3 on N-termina! helix 
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and Arg23, Arg25, Arg26, Arg34, Arg36 and Lys33 on the C-terminal helix. One 
negative cluster is composed of Glu6, Glu8 on the N-terminal helix and Glu32, Glu37, 
and Glu39 on the C-terminal helix. Another cluster near the regular central loop 
includes Glul8 and Glu22. 
The sequential and medium-range NOEs observed in the 
2D ^^N-decoupled-NOESY, and 3D ^^N-edited-HSQC-NOESY spectra were summarized 
in Fig. 3.3E for reference. 
34 
A. 
/ 〜 ， 
• 、二 < f 
,“丨’ . J ^ 
K f i.- � 
J - J ：> ^ W H ^ V ^ A 
> 
‘ i 厂 ； 
J , c 4 � 
B'.- -- - ； N - * - • 
J -




食 赛 « I 
35 
E. l|o I 20 I 30 40 
G S P R T E Y E A C R V R C Q V A E H G V E R Q R R C Q Q V C E K R L R E R E G R R E 
i/�N(/V+l> — — 一 — — ' — — “ 一 一 
dAU+1) 
<W',''+” ；；：；^ ^^^ 
rf„�(,V+2> ——^——— 
一"•“严 _ = - - ~ 
d^iU+i) —— ~ — — 
‘�(/V+4) - = = — ~ ‘ — 
Fig. 3.3 (A) Stereo-view superpositions of the final restrained structures of Luffin 
P I obtained by superposition of backbone atoms of the well-defined region of the 
molecule, encompassing residues 5 to 39. Two a-helices (green), central loop (red), 
random coil C- and N- terminus (magenta) and four cysteine residues (yellow) are 
displayed. (B) The ribbon representations of the lowest-energy model by 90" 
rotation along the x axis. Four cysteine residues involved in disulfide bonds are 
shown as stick representations. Front (C) and back (D) view of the electrostatic 
potential map of the surfaces of Luffin PI. Electrostatic surface potential in blue is 
positive, that in red is negative, and that in white is neutral. Figures were 
generated with MOLMOL The ribbon model and side chains of the charged 
residues are shown in reference to the electrostatic surface model. Side chains of 
10 arginine and 1 lysine residues are shown in blue; side chains of eight glutamates 
are shown in red. The Sy atoms are shown as balls. (E) Amino acid sequence of 
Luffin P I and schematic representation of the sequential and medium-range NOE 
connectivities. 
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3.2.5 In vitro N-glvcosidase activity of Luffin P I 
The N-glycosidase activity of Luffin P I was investigated on rRNA extracted 
from rabbit reticulocyte lysate. As shown in Fig. 3.4, a positive control, in which 
TCS was used, showed a released fragment in the presence of aniline treatment 
while the negative control (DEPC-H20 with or without aniline treatment) did not 
show the released fragment. However, no such released fragment could be 
observed in Luffin PI. Therefore, Luffin P I does not have N-glycosidase activity. 
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Fig 3.4 N-glycosidase activity of Luffin PI. 1 mM TCS served as the positive 
control while DEPC-H2O was the negative control. Different concentration of Luffin 
P I (0.01 mM, 0.1 mM, 1 mM and 10 mM) were tested for their N-glycosidase 
activity. Only the RNA treated with TCS and aniline showed the released fragment. 
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3.3 Discussion 
Two type I RIPs, Luffin A and B with molecular masses of 27 and 28 kDa 
respectively, have been isolated from seeds of Luffa cylindrico. Several small 
proteins, including 9K-PSI (Watanabe et al., 1990), Luffin S (Gao et al., 1994), Luffin 
P I and Luffacylin (Parkash et al., 2002) with a molecular weight about or less than 
10 kDa have also been isolated from the seeds of the same species with inhibitory 
activities on the cell-free protein synthesis comparable or even stronger than Luffin 
A and B. The molar concentrations of proteins required for 50% inhibition of 
protein synthesis (iCso) were: Luffin A, 5.4 nM; Luffin B, 19.8 nM; Luffin S, 0.34 nM; 
Luffin PI, 0.88 nM; 9K-PSI, 140 nM; Luffacylin, 0.14 nM. These small RIPs are 
characterized by a high content of arginine and glutamate residues and thus 
designated ARGPs (Ishihara, Sasagawa, & Sakai, 1997). 
The N-terminal sequence of Luffin P I exhibits a pronounced similarity to that 
of 7.8 kDa Luffacylin. In a separate study, four ARGPs with molecular weights of 5, 
6.5, 12.5 and 14 kDa, respectively, have been isolated from L cylindrica, but not 
assayed for translation inhibition activity (Ishihara et al., 1997). The 6.5k-ARGP has 
almost identical sequence with Luffin P I except that the former has two extra 
residues Pro-Arg at the N-terminus and two extra residues Val-Asp at the 
C-terminus. Luffin P I and 6.5k-ARGP from the seeds of L. cylindrica might be 
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encoded by a single gene but the formal protein arises by removing two residues 
from both the N- and C-termini of the 6.5k-ARGP. Arginine and glutamate are the 
most abundant amino acids in Luffin PI. The amount of arginine and glutamate 
are 26% and 19%, respectively. Arginine and glutamate are distributed 
throughout the polypeptide sequence but small clusters also present in the 
C-terminal half of the polypeptide chain. 
in previous study, gel filtration chromatography results showed that this 
peptide formed homotetramer in hydrophobic buffer and depolymerized to 
homodimer in hydrophilic buffer. It was also proposed that the polymerization of 
Luffin P I generated the folds required for its N-glycosidase activity (Li et al., 2003). 
Since the shape of Luffin P I in solution is unknown, using gel filtration 
chromatography for mass analysis may be inaccurate. In contrast, static light 
scattering (SLS) data are based on the scattering of light from proteins, which 
provides an accurate means of determining the molecular mass, without influenced 
by the molecular shape or hydrodynamic parameters (Wen et al., 1996). From the 
SLS results, it showed that Luffin P I has a monomeric rather than a homodimeric 
nature in hydrophilic condition because its molecular weight is about 5.4 kDa and 
without any peaks at around 10.8 kDa. In addition, Luffin P I global secondary 
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structure was evaluated using far-UV CD spectroscopy and confirmed that its 
secondary structure is mainly helical as it has 81% a-helix structure content. 
After solving the 3D structure of Luffin PI, we found that its conformation 
differs dramatically from those of all previously described families of RIPs. In 
general, type I and the A-chain of type II RIPs have two domains, consisting of six 
a-helices and a six stranded mixed p-sheet in the large N-terminal domain. In the 
small C-terminal domain, there is a distinguish anti-parallel p-sheet and two 
a-helices with a bend in the middle (a-helix G and H). In ricin with molecular 
weight of 32 kDa, the conserved active site residues TyrSO, Tyrl23, Glul77, ArglSO 
and Trp211 are located at the cleft formed by these two domains (Robertus & 
Monzingo, 2004). Despite that, from the 3D solution structure of Luffin PI, it 
indicates that this small RIP structurally had no relation to other typical 
N-glycosidase proteins. Luffin P I represents a completely novel form of small RIP 
and sequence alignment cannot find these conserved active residues. This result 
indicated that this small RIP is likely to have a totally different mechanism of action. 
Another evidence of Luffin P I is likely to have another mechanism of action is 
that Luffin P I does not show N-glycosidase activity (Fig. 3.4). No released 
fragment could be observed even after incubating the RNA with Luffin P I at 
concentration as high as 10 mM, which is much higher than its IC50 of protein 
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synthesis inhibitory activity. This result is reasonable because we show that Luffin 
P I does not show any RIP conserved active site residues and not undergo 
polymerization to generate the folds required for its N-glycosidase activity as 
suggested by Li and coworkers. However, our result shows that Luffin P I does not 
have N-glycosidase activity, which does not match the previous study done by Li 
and coworkers. This may be due to the contaminants in the Luffin P I purified by Li 
and coworkers as they purified it directly from the seed of L cylindrical. It is hard 
to purify Luffin P I without other contaminants, which may have similar size as 
Luffin PI, from the seeds without any protein purification tags. Hence, the 
N-glycosidase activity of Luffin P I shown by Li and coworkers may be due to those 
contaminants. 
While Luffin P I is positively charged at neutral pH, with a calculated pi of 9.3, 
the surface of ribosome is negatively charged. Therefore, charge-charge 
interaction between Luffin P I and the ribosome may be part of the mechanisms of 
Luffin P I to inhibit protein synthesis. It have been shown that electrostatic 
interaction assists the docking of RIPs on specific ribosomal subunits and the 
interactions between the basic surface residues of RIP and acidic residues of 
ribosomal proteins facilitates their encounter and increases the reaction rate above 
the expected diffusion limit (Korennykh et al., 2007). Similarly, electrostatic 
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interaction has been shown to contribute to rapid target localization of the 
ribotoxin-restrictocin (Korennykh et al., 2007). Hence, the positive charges of 
Luffin P I may facilitate Luffin P I to get to its target site on the ribosome. 
Additionally, it is interesting to note that the major positively charged surface is not 
on the "face" but instead on the "s ide� of the two-helix bundle, and residues from 
the C-terminal helix contribute much to this positive region (Fig. 3.3C and D). The 
positive or negative potentials are closely distributed at the surface. Owing to the 
larger fraction of charged surface residues, the contribution of electrostatic 
complementarity which is revealed as hydrogen bonds and salt bridges across the 
binding interface is important. Electrostatic complementarity may facilitate the 
localization of other cellular proteins and play an important role in the inhibition 
activities. The rigid helix-loop-helix model stabilized by the formation of disulfide 
bonds also provides a scaffold for other cell component to interaction. 
In order to know more about how the structure of Luffin P I contributes to its 
activity, proteins with similar structure as Luffin P I had been searched in DAL! 
database. A query to the DALI server (Holm & J. Park, 2000) retrieved a number of 
anti-parallel two-helix that exhibit some structural similarity to Luffin PI. However, 
the two disulfide bonds linking two helices pattern of the peptide is relatively rare 
in protein or peptide structures. A trypsin inhibitor from seeds of Vcronicc 
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hederifolia (VhTI) exhibited 38% identity in amino acids to Luff in PI. A truncated 
VhTI, which is 42% homology in sequence to Luff in P I has been synthesized and 
co-crystallized with trypsin (Conners et al., 2007). Both the native VhTI and 
truncated VhTI are rich in charged residues (Fig. 3.5A). The truncated VhTI 
inhibitor forms a non-covalent complex with trypsin in a substrate-like manner, 
hence occupying the entrance of the active site of the protein competitively and 
preventing substrate from binding. This peptide is structurally similar to Luffin P I 
{Fig. 3.5B) (RMSD = 1.183 A over 21 Ca). However, the two anti-parallel helices 
are much shorter compared to that of Luffin PI. Anti-HIV activities have been 
associated with the proteinaceous proteinase inhibitors (Gustafson et al., 1994). A 
DALI search of structures in the protein data bank (PDB) cannot identify the 
truncated VhTI. This may be due to the relatively small size of this peptide, which 
limits the validity of the DaliLite pairwise comparison analysis. Both polypeptides 
are featured by a conserved 'twin C X 3C' motif in which there are three interposed 
residues between the two cysteines. In Luffin PI, these two motifs are separated 
by 12 residues and in VhTI, are separated by 13 residues. 
The structural similarity between Luffin P I and VhTI inhibitor may also provide 
some clues about the functional features of Luffin PI. The truncated VhTI inhibitor 
complexed to trypsin revealed the interaction between them. The helix-loop-helix 
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motif stabilized by two disulfide bonds provides a scaffold to the inhibitor. The 
interaction of VhTI inhibitor and trypsin is defined mainly by electrostatic 
complementarity and the binding is achieved through hydrogen bonding and salt 
bridge network across the binding interface. This interaction blocks the active site 
of the protein and competitively prevents the substrate from binding. Similar to 
VhTI inhibitor, Luffin P I may inhibit protein synthesis by selectively binding to some 
cellular components. This recognition process is determined by both geometrical 
and charge complementarity. 
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Fig. 3.5 (A) Sequence alignments of Luffin PI, native VhTI and truncated VhTI. 
Identical residues are indicated by star. (B) Solution structure of Luffin P I (green) 
and crystal structure of truncated VhTI inhibitor (purple; PDB code: 2PLX, chain A) 
are superimposed and shown in ribbon representations. Disulfide bonds are shown 
as stick representations. 
46 
Overall, in neutral pH, Luffin P I is positively charged with a helix-loop-helix structure 
which is stabilized by two disulfide bonds. We also found that Luffin P I does not 
have RIP conserved active site residues, not undergo polymerization to form 
homodimer as suggested by Li and coworkers not have N-glycosidase activity. 
Since there is a discrepancy between our data and the previous reported data, we 
do not proceed to use it for nanoparticle construction. 
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Chapter 4 - Generation of positively charged CS 
particles and Bllb incorporation 
4.1 Introduction 
Since chitosan (CS) is low immunogenic, biodegradable and biocompatible, it 
would be interesting if chitosan (CS) can be developed as nanoparticle (NP). As the 
pKa of the amine groups on CS are around 6.5, the amine groups will be protonated 
under physiological pH and hence CS will be positively charged (+ve). Therefore, if 
unmodified CS is used for NPs generation, the CS NPs will be +ve. 
There are several methods have been used to generate positively charged (+ve) 
CS NPs: 
1. lonotropic gelation method: When suitable weight ratio of polyanion, like TPP 
(tripolyphosphate), and CS are mixed, +ve CS NPs will be generated. It is based on 
the charge-charge interaction between the negatively charged (-ve) groups of 
polyanion and the protonated amine groups of CS. The size of +ve CS NPs largely 
depends on the ratio of polyanion and CS (Pan et al., 2002). 
2. Microemulsion method: In the presence of n-hexane, the amine groups of CS 
will conjugate with gluaraldehyde after stirring for a period, which results in +ve CS 
NPs generation (Tiyaboonchai et al., 2007). 
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3. Emulsification solvent diffusion method: An organic solvent is mixed with CS 
solution under high pressure and mechanical stirring. Then the mixture is diluted 
with a 5 liter of water to generate +ve CS NPs (Shabouri, 2002). 
In the present study, ionotropic gelation method was chosen because it is a 
simple method using mild conditions and aqueous solvent whereas the other two 
methods require harsh and time consuming processes with the use of organic 
solvent, which is difficult to remove completely after the reactions. 
It is not an easy task to develop CS to be a carrier for positively charged (+ve) 
peptide or protein drug as CS is also +ve under physiological pH. Currently, only 
protein drugs with pi lower than 6, such as insulin, have been incorporated into +ve 
CS NPs (Zhang et al., 2010). Therefore, various approaches were put into trial in 
the present study in order to incorporate +ve peptide into +ve CS NPs. 
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4.2 Results 
4.2.1 +ve CS NPs generation 
TPP was used as polyanion to interact with CS for +ve CS NPs generation. 
Table 2 shows different combinations of CS solution and TPP solution mixture to 
produce +ve CS NPs. As CS solution was prepared by dissolving CS powder into 3% 
acetic acid, the pH of CS solution should be increased to 5.5 by adding 1 M sodium 
bicarbonate (NaHCOs) before mixing it with TPP solution. After +ve CS NPs 
formation, the pH of the NPs solution was increased to 7.4 by adding 1 M NaHCOs-
It was found that 5 ml of 0.4% CS solution and 2ml 0.4% TPP solution mixture gave 
spherical +ve CS NPs with diameter less than 200 nm (Fig. 4.1) while other 
combinations of CS and TPP solution produced larger NPs (> 200 nm) or no NPs 
formation (Fig. 4.2). 
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Chitosan solution TPP solution 
Concentration Volume Concentration Volume 
(w/v) (ml) (w/v) (ml) 
0.3% 5 0.3% 2 
0.3% 5 0.4% 2 
0.3% 5 0.5% 2 
0.4% 5 0.3% 2 
0 . 4 % i Q M ： I 
0.4% 5 0.5% 2 
0.5% 5 0.3% 2 
0.5% 5 0.4% 2 
0.5% 5 0.5% 2 
Table 2 Different combination of chitosan solution and TPP solution mixture. The 
pH of CS solution was increased to 5.5 before adding into TPP solution drop by drop. 
The pH of the NPs solution also was increased to 7.4 when the reaction was finished. 
All combinations gave particles or precipitate but only one combination (the bolded 
and underlined one) gave CS particles with diameter smaller than 200 nm. 
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solution drop by drop. The shape of +ve CS particles is spherical and the diameter 
is less than 200 nm. 
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• I M I f l 
Fig. 4.2 SEM photos of some unsuccesssful examples of +ve CS NPs generation. 
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(A) No particles could be formed when 5 ml of 0.3% CS solution mixed with 2 ml of 
0.3% TPP solution. (B) +ve CS NPs with diameter larger than 200 nm was formed if 
5 ml of 0.5% CS solution mixed with 2 ml of 0.5% TPP solution. 
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4.2.2 Bllb incorporated +ve CS NPs generation 
Two methods were used to incorporate Bllb into +ve CS NPs. For the first 
one, 1 mg of Bllb powder was dissolved in 5 ml 0.4% of CS solution before adding it 
drop by drop into 2 ml 0.4% of TPP solution with stirring for 1 hour. Another way is 
to generate +ve CS NPs first； then dissolve 1 mg of Bllb powder in 1 ml of 18.45 
mg/ml +ve CS NPs, then finally, add 200 ul of 3.28 \xM DTSSP, a chemical cross-linker 
into the mixture of +ve CS NPs and Bllb with stirring for 1 hour, which will generate 
+ve CS NPs linked to Bllb by DTSSP (+ve CS-DTSSP-Bllb NPs). 
The morphologies of NPs generated by two methods were observed by SEM. 
The size and shape of NPs generated by the first method was similar as those shown 
in Fig. 4.1 while those produced by the second method are shown in Fig. 4.3. The 
diameter of +ve CS-DTSSP-Bllb is a bit larger than +ve CS NPs but still smaller than 
200 nm, and the shape is spherical. 
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Fig. 4.3 SEM photo of +ve CS-DTSSP Bllb NPs. These particles were generated by 
adding chemical cross-linker, DTSSP, to the mixture of Bllb and +ve CS NPs drop by 
drop. The overall diameters of these particles are less than 200 nm and their 
shape are spherical. 
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To check whether there was any peptide trapped in +ve CS NPs, NPs were 
re-dissolved in 3% acetic acid with 5% P-mercaptoethanoI, which can cleave the 
disulfide bonds between Bllb and +ve CS NPs formed by DISS P. After the NPs were 
completely re-dissolved, they were loaded in 15% SDS-PAGE and the gel was then 
stained by Coomassie blue to see whether there was any band corresponding to Bllb. 
A band with molecular size corresponding to Bllb could be observed in NPs 
generated by the second method but none in those generated by the first method 
(data not shown), which means that only the second but not the first method can 
successfully trap Bllb into +ve CS NPs. 
To find out the amount of peptide trapped in the NPs, +ve CS-DTSSP-Bllb NPs 
was centrifuged at 14, 000 rpm and 4°C for 10 minutes after stirring of DTSSP, +ve 
CS NPs and Bllb mixture for 1 hour. The amount of unbound Bllb was determined 
in the supernatant by UV spectrophotometry at 205 nm. Then Bllb encapsulation 
efficiency and loading capacity were calculated as 40.40% and 2.16% respectively. 
4.2.3 In vitro release study 
The in vitro release of Bllb from the NPs was performed under different pH at 
37�C in PBS for 36 hours. It showed that Bllb was not released easily from the NPs 
under pH 4, 7.4 and 10 as shown in Fig. 4.4. 
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Fig. 4.4 In vitro release of +ve CS-DTSSP Bllb NPs at 37°C at different pH conditions 
in PBS. At pH 4, 7.4 and 10, the percentages of Bllb released from the NPs were 
low over the period of 36 hours. This may probably be due to the strong covalent 
linkage between +ve CS NPs and Bllb formed by DISS P. The results shown are 
mean 土 SEM of three separate experiments. 
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4.2.4 In vitro cytotoxicity test 
Cytotoxicity of +ve CS NPs, Bllb and +ve CS-DTSSP-Bllb NPs on HeLa and 
J774A.1 cell lines were examined. After 72 hours incubation, as shown in Fig. 4.5, 
IC50 of Bllb towards HeLa and J774A.1 were 56.99 |ig/ml (22.26 piM) and 52.57 
^ig/ml (20.51 nM) respectively while IC50 of +ve CS-DTSSP-Bllb NPs towards HeLa 
and J774A.1 were 32.21 mg/ml and 17.47 mg/ml respectively. Also, +ve CS NPs 
was not toxic to both cell lines at concentration 42.50 mg/ml. In order to have a 
fair comparison on the toxicity between Bllb and +ve CS-DTSSP-Bllb NPs, the 
amount of Bllb trapped in the NPs was calculated. Since we have already 
determined the Bllb loading capacity of NPs, the concentration of Bllb trapped could 
be easily calculated by the following equation: Loading capacity (%) x concentration 
of the NPs (mg/ml) = the concentration of peptide trapped (mg/ml). By using this 
equation, the actual concentration of Bllb in 32.21 mg/ml and 17.47 mg/ml of the 
NPs (the IC50 of +ve CS-DTSSP Bllb NPs towards HeLa and J774A.1) were 695 |ig/ml 
(271.42 nM) and 377 |ig/ml (147.26 \xW\) respectively. 
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Fig 4.5 In vitro cytotoxicity tests of (A) Bllb and (B) +ve CS-DTSSP Bllb NPs on HeLa 
and J774A.1 cells. The drugs incubated with the cells for 72 hours before 
terminating the experiments by adding MTT The results shown are mean ± SEM 
of three separate experiments. 
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4.3 Discussion 
CS has the ability to form gel spontaneously when it interacts with multivalent 
polyanions to form both inter and intramolecular cross linkages with polyanions (Fig. 
4.6). In this project, tripolyphosphate (TPP) was chosen for +ve CS NPs formation 
owing to its non-toxic property and quick gelling ability. Using TPP also allows the 
process of NPs formation to be manipulated in mild conditions, like room 
temperature stirring and without using high voltage, to prevent the trapped 
peptides from denaturation in high temperature (Gan et al., 2005). 
CS solution was prepared by dissolving CS powder into 3% acetic acid because 
CS is not soluble in solution with neutral pH. However, some peptides may be 
denatured under very low pH. As a result, the pH of CS solution should be 
increased so as not to denature the peptides during the NPs formation. The pH of 
CS solution should not be higher than the pKa (6.5) of its protonated amine groups 
as CS should remain positively charged to interact with TPP during the NPs 
formation (Fig. 4.6). Therefore, the pH of CS solution was increased to 5.5 in this 
study. Sodium bicarbonate (NaHCOs) but not other alkaline was used to increase 
the pH of CS solution, as other alkaline, like NaOH, would easily result in CS 
aggregation when the alkaline is adding into CS solution. This may be due to the 
strong interaction between O K and protonated amine groups, which allow OH" to 
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act as a bridge between two CS molecules. (Zhong et al., 2011). 
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Fig. 4.6 lonotropic cross linking of TPP and CS. The negative charges of TPP 
interact with the positive charges of protonated amine groups of CS molecules, 
which bring two CS molecules together closely. 
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After +ve CS NPs are generated, the pH should be increased from 5.5 to 7.4 
because the NPs will be used in mammalian cell culture to test their toxicity towards 
tumor cell lines. Similarly, NaHCOa was used to increase the pH. At pH 7.4, the 
amine groups of CS will be deprotonated and hence +ve CS NPs will become 
insoluble and form aggregate. But in the presence of NaHCOs, +ve CS NPs will not 
form aggregate even at pH 7.4. The mechanism underlying the ability of NaHCOs 
to promote the solubility of CS at pH 7.4 is not clear. It may probably be due to 
the reason that HCOs" has special affinity to the amine groups in CS. This special 
interaction may reduce the hydrogen bond network of CS, which help CS to remain 
stable at pH 7.4 (Muzzarelli, 2003; Zhong et al., 2011). 
To generate a high yield of +ve CS NPs, volume ratio of CS to TPP was found to 
be within the range of 3:1 to 6:1 (Gan et al., 2005). Since positively charged Bllb 
was trapped in +ve CS NPs in our study, the ratio of CS to TPP was decreased to 2.5:1 
to ensure that there is enough of divalent TPP to interact with CS molecule on the 
one side of TPP and interact with Bllb on the other side. From Fig. 4.1, it showed 
that +ve CS NPs with diameter less than 200 nm could still be generated when the 
ratio of CS to TPP decreased. 
After knowing how to generate small +ve CS NPs； Bllb was mixed with CS 
solution and then added into TPP solution. To check whether Bllb was trapped in 
65 
the NPs, the NPs was re-dissolved into 3% acetic acid and loaded to 15% SDS-PAGE 
to confirm if there is a band corresponding to Bllb in the gel. However, no band 
could be observed in this sample, which means no Bllb or too little Bllb was trapped 
in +ve CS NPs. A possible reason is that the divalent TPP may prefer interacting 
with two CS molecules rather than Bllb on its one side and CS molecule on the 
other. 
Another method had been manipulated to incorporate Bllb into +ve CS NPs. 
A chemical cross-linker, DTSSP, was used to tightly link +ve CS NPs with Bllb by 
forming a strong covalent bond between them. As DTSSP has a disulfide bond in 
the middle, Bllb could be released from the NPs when this bond is cleaved inside the 
cells (Fig. 4.7). Since lysosomal thiol reductase, which has the ability to catalyze 
disulfide bond reduction, exists in the lysosome (Arunachalam et al., 2000), the 
disulfide bond of DTSSP would be reduced to release Bllb from the NPs after the NPs 
is endocytosed. As a result, DTSSP was manipulated to trap Bllb into +ve CS NPs. 
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Fig 4.7 Structure of DISS P. This chemical cross-linker is thiol-cleavable as 
there is a disulfide bond in the middle. It also has two NHS-ester groups, which 
can react with primary amine group to form covalent amide bond. 
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+ve CS NPs was firstly synthesized in the same way as mentioned above, then 
SEM photos of +ve CS-DTSSP Bllb NPs were taken after adding DTSSP into the 
mixture of +ve CS NPs and Bllb. Since some DTSSP may bind with both +ve CS NPs 
rather than one NPs and one Bllb molecules, the diameters of +ve CS-DTSSP Bllb 
NPs are bigger than +ve CS NPs but still smaller than 200 nm and their shapes are 
sphere-like but not as uniform as +ve CS NPs (Fig. 4.3). 
In vitro release study on +ve CS-DTSSP Bllb NPs has been done to investigate 
whether Bllb will non-specifically release from the NPs during blood circulation. 
PBS at 3 7 � C at different pH were used to mimic the blood circulating in different 
parts of human body. As shown in Fig. 4.4, Bllb was not released from the NPs at 
pH 4, 7.4 and 10, which indicates that Bllb was not easily lost from the NPs during 
blood circulation. 
+ve CS NPs, +ve CS-DTSSP NPs and Bllb had been tested for their cytotoxicties 
towards both HeLa, human cervical tumor, and J774A.1 cell lines' mouse 
monocyte-macrophage tumor. As expected, +ve CS NPs was not toxic to both 
tumor cells even at concentration 42.50 mg/ml. The IC50 of Bllb to HeLa and 
J774A.1 were similar, which were 56.99 pig/ml (22.26 |iM) and 52.57 ^g/ml (20.51 
piM) respectively, while IC50 of +ve CS-DTSSP-Bllb NPs to HeLa and J774A.1 varied, 
which were 32.21 mg/ml and 17.47 mg/ml respectively. One possible reason to 
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explain this observation is that they have different ways to get into the cells. Since 
Bllb can get into cytoplasm by interacting with the negatively charged proteins on 
the membrane, it should get into both tumor cells in similar rate. However, the 
NPs have to get into the cells by endocytosis. Based on the fact that more active 
endocytosis occur in macrophage, more +ve CS-DTSSP Bllb NPs can get into J774A.1 
than HeLa and hence toxicity of+ve CS-DTSSP Bllb NPs to J774A.1 is higher. 
To assess whether +ve CS-DTSSP Bllb is a good NPs drug, the first parameter 
to be determined is whether the toxicity of Bllb will change after binding with the 
NPs. Consequently, the concentration of +ve CS-DTSSP Bllb NPs was converted 
into the concentration of Bllb for the toxicity comparison. After converting the 
concentration, the IC50 of Bllb and +ve CS-DTSSP Bllb NPs to HeLa were 56.99 [xg/m\ 
(22.26 nM) and 695 ^g/ml (271.42 liM) respectively while to J774A.1 were 52.57 
|ig/ml (20.51 l^IVI) and 377 \xg/rx)\ (147.26 [iM) respectively. So, +ve CS-DTSSP Bllb 
NPs was at least 7-fold and at most 12-fold less toxic than Bllb. The lowered 
toxicity of+ve CS-DTSSP Bllb NPs may be due to the strong disulfide bond between 
CS molecule and Bllb. And the thiol reductase in lysosome may not cleave the 
disulfide bonds easily and hence not all Bllb can be released from the NPs. 
Therefore, the toxicity of+ve CS-DTSSP Bllb NPs is greatly reduced. 
To summarize, +ve CS NPs with diameter less than 200 nm was generated and 
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Bllb was successfully incorporated into +ve CS NPs by DTSSP. Although Bllb was 
not easily detached from the NPs, its toxicity was 7 to 12-fold lower than Bllb alone. 
Hence, it is essential to further optimize the +ve CS-DTSSP Bllb NPs for improving its 
toxicity effect on cells. 
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Chapter 5 一 Generation of negatively charged CS 
particles and Bllb incorporation 
5.1 Introduction 
Since CS carries the positive charges, +ve Bllb cannot be easily incorporated 
into CS NPs. in addition, it was shown that negatively charged substances, such as 
DNA and RNA, can have high encapsulation efficiency in +ve CS NPs. For instance, 
DNA encapsulation efficiency is as high as 90% in +ve CS-DNA NPs (Turan & Akbuga, 
2011). The encapsulation efficiency can be increased to nearly 100% if the zeta 
potential of +ve CS NPs is around +18 mV (Sun et al” 2011). Zeta potential is 
defined as the nature of the electrostatic potential near the surface of a NP. In 
other words, zeta potential is always considered as surface charges of NPs. 
Therefore, we have changed the charges of CS from positive to negative by chemical 
modification so that the positively charged peptide, like Bllb, can efficiently interact 
with negatively charged (-ve) CS to generate high peptide loading CS NPs. 
To generate -ve CS NPs, the amine groups of CS should be modified to 
negative charge bearing groups. Bodnar and coworkers showed that by adding 
different types of di- or tricarboxylic acid in CS solution with CDI (a chemical 
reagent), CS NPs with various charges can be generated (Bodnar et al., 2005). 
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Since their -ve CS NPs generation condition is not suitable for incorporating peptide, 
we have modified the protocol so that the peptide will not be denatured or lost. 
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5.2 Results 
5.2.1 -ve CS NPs generation 
Dissolving CS powder into 2% HCI instead of 3% acetic acid forms 1% CS 
solution for the generation of -ve CS NPs. Different weights of tartaric acid (TA) or 
critic acid (CA) were dissolved in distilled water and by adding 2 M NaOH, the pH 
values of both carboxylic acid solutions were adjusted to 6.5. CS NPs were 
generated by adding both CDI powder and CS solution into different carboxylic acid 
solutions. The zeta potential of the NPs was checked to see whether the charges 
of CS NPs were changed from +ve to -ve. As shown in table 3, -ve CS NPs could be 
generated by adding either 0.205 g TA or 0.287 g CA. Since -ve CS NPs generated 
by adding TA creates the most negative zeta potential, all -ve CS NPs in latter 
experiments would be generated by adding 0.205 g TA. As shown in Fig. 5.1； the 
diameter of-ve CS NPs was smaller than 100 nm. 
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Substance Weight of acid Weight of CS solution Zeta potential ± 
added added (g) CDI added (g) added (ml) SEM (mV) 
Tartaric acid 0.102 0.406 1 +3.56 士 0.17 
(TA) 0.205 0.811 1 -26.56 士 1.31 
TA+Bllb 0.205 0.811 1 -12.03 土 0.75 
TA + Cy5 + Bllb 0.205 0.811 1 -15.32 士 1.11 
Citric acid (CA) 0.143 0.406 1 +4.22 士 1.55 
0.287 0.811 1 -0.26 士 0.15 
Table 3 Reaction conditions of synthesizing -ve CS NPs and its average zeta 
potential. N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (CDI) 
was used to link the carboxylic acid on chitosan (CS) molecule by forming an amide 
bond. The best formula to form -ve CS NPs was bolded as its zeta potential is the 
most negative. By using the best formula, Cy5, a fluorescent dye； and Bllb were 
successfully incorporated into -ve CS NPs with negative zeta potential. 
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Fig 5.1 SEM photo of -ve CS NPs. The diameters of the particles were smaller 
than lOOnm with spherical shape. 
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5.2.2 -ve CS-Bllb NPs generation 
In order to incorporate Bllb into -ve CS NPs to generate -ve CS-Bllb NPs, 1 mg 
Bllb powder was dissolved into 1 ml CS solution. This mixture was then added into 
TA solution drop by drop in the presence of CDI. The zeta potential of -ve CS-Bllb 
NPs was measured as -12.03 土 0.75 (Table 3), which is less negative when 
compared with -ve CS NPs. As shown in Fig. 5.2, the zeta potential of -ve CS-Bllb 
NPs was statistically significant lower than that of the -ve CS NPs (P<0.01). 
The size of -ve CS-Bllb NPs was examined by SEM and was found that it was 
smaller than 100 nm (Fig. 5.3). 
A band corresponding to Bllb was found in -ve CS-Bllb NPs by dissolving the 
NPs in 3% acetic acid and loading it into 15% SDS-PAGE (data not shown). To find 
out the amount of Bllb trapped in the NPs, -ve CS-Bllb NPs was centrifuged at 14, 
000 rpm and 4 � C for 10 minutes after stirring of the CS solution, CDI, TA solution 
and Bllb mixture for 1 hour. The amount of unbound Bllb was determined in the 
supernatant by UV spectrophotometry at 205 nm. Then Bllb encapsulation 
efficiency and loading capacity were calculated as 93.2% and 5.09% respectively. 
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Fig. 5.2 A bar chart showing the zeta potential of -ve CS NPs and -ve CS-Bllb NPs. 
After incorporating Bllb into -ve CS NPs to generate -ve CS-Bllb NPs, its zeta 
potential was significantly decreased when compared with -ve CS NPs. The results 
are expressed as mean ± SEM of three separate experiments. One tailed paired 
t-test was performed to compare their zeta potential differences. **P<0.01, the 
zeta potential of -ve CS-Bllb NPs was statistically significantly less negative than that 




Fig. 5.3 SEM photo of -ve CS-Bllb NPs. The particles have diameter less than 100 
nm but slightly bigger than the -ve CS NPs and is sphere-like shape. 
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5.2.3 In vitro release study 
-ve CS-Bllb NPs was suspended in PBS at pH 4, 7.4 or 10 to mimic the 
differences in various part of the body. As shown in Fig. 5.3, the release rates of 
the NPs at pH 4, 7.4 and 10 were similar. The initial drug release rates were high (a 
burst release) from 0 - 8 hours and the release rates were slower and still 
detectable between 8 - 7 2 hours. Around 80% Bllb was released from the NPs at 
all pH values over the period of 72 hours. Bllb tends to be released after 72 hours 
as the positive slopes could still be observed. 
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Fig. 5.3 In vitro release study of-ve CS-Bllb NPs in PBS with different pH at 37 °C. 
Burst release of Bllb occurred in the first few hours of incubation and the release 
became sustainable after 24 hours. Around 80% of Bllb was released at 72 hours 
in all PBS solutions at different pH. The results shown are mean 土 SEM of three 
separate experiments. 
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5.2.5 Localization study of-ve CS-Bllb NPs 
In order to study the intracellular localization of -ve CS-Bllb NPs in HeLa and 
J774A.1 cells, Cy5, a fluorescent dye, and Bllb were incorporated together into -ve 
CS NPs to generate -ve CS-Cy5-Bllb NPs by the method similar to -ve CS-Bllb NPs 
generation. The size and zeta potential of—ve CS-Cy5-Bllb NPs was similar to the 
generation o f - v e CS-Bllb NPs (Fig. 5.4 and Table 3). The locations of the NPs in 
both cells were represented as red signals while the bright field images of the cells 
were also captured (Fig 5.5). After overlaying two images, it was found that -ve 
CS-Cy5-Bllb NPs could get into both types of cells. Interestingly, not all HeLa cells 
could uptake the NPs (Fig 5.5B), but all J774A.1 could (Fig. 5.5A). 
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Fig. 5.5 Intracellular localization of -ve CS-Cy5-Bllb NPs as measured by 
confocal microscope. (A) J774A.1, (B) HeLa. -ve CS-Cy5-Bllb NPs was found 
getting into both J774A.1 and HeLa successfully. Obviously, all J774A.1 but not 
HeLa could pick up the NPs. 
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5.2.6 In vitro cytotoxicity test 
Cytotoxicity of -ve CS NPs and -ve CS-Bllb NPs on HeLa and J774A.1 cell lines 
were examined. After incubation for 72 hours, as shown in Fig. 5.6, IC50 of -ve 
CS-Bllb NPs on HeLa and J774A.1 cells were 9.06 mg/ml and 2.10 mg/ml respectively. 
-ve CS NPs was not toxic to both cell lines even at a concentration as high as 18.90 
mg/ml. The concentration of Bllb trapped in -ve CS-Bllb NPs was calculated for 
comparing its toxicity with free Bllb. The following equation was used for the 
calculation: Loading capacity (%) x concentration of the NPs (mg/ml) = the 
concentration of peptide trapped (mg/ml). By using this equation, the actual 
concentration of Bllb in 9.06 mg/ml and 2.10 mg/ml of the NPs (the IC50 of -ve 
CS-Bllb NPs towards HeLa and J774A.1) were 460.24 昭/ml (179.77 i^M) and 106.68 
|ig/ml (41.67 |iM) respectively. 
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Fig. 5.6 In vitro cytotoxicity tests of -ve CS-Bllb NPs on HeLa and J774A.1 cells. 
The drugs incubated with the cells for 72 hours before terminating the experiments 
by adding MTT. The IC50 of the NPs on HeLa and J774A.1 cells were 179.77 |iM and 




Previous studies showed that charge-charge interaction between DNA and +ve 
CS NPs gives high encapsulation efficiency (Sun et al., 2011; Turan & Akbuga, 2011), 
therefore we have modified the charge of CS from +ve charge to -ve charge to 
increase the +ve peptide, Bllb； encapsulation efficiency. 
A report suggested that negatively charged CS NPs (-ve CS NPs) can be 
generated by adding carboxylic acid and CDI (Bodnar et al., 2005). The mechanism 
of CDI, a chemical reagent, is to react with carboxylic acid to form an active 
intermediate first, and then the intermediate is attacked by amine to form amide 
(Fig. 5.7). In order to lower the production cost and not to denature Bllb, we have 
modified the -ve CS NP production protocol to trap Bllb in the NPs: 
1. 2% HCI instead of 3% acetic acid was used to dissolve CS powder to generate CS 
solution because CDI will also react with acetic acid which links to CS molecules. 
This will decrease the number of amine groups on CS molecules reacting with 
tartaric acid (TA) or critic acid (CA). 
2. The whole NP generation process was performed in the cold room (4�C) to 
ensure that the peptide, Bllb, was not denatured. 
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3. Fewer amounts of carboxylic acid and CDI were used to lower the production 
cost. The total volume of reaction was also decreased to generate higher 
concentration of-ve CS NPs. 
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Fig. 5.7 Systematic scheme of amide formation with the help of CDI. Carboxylic 
acid reacts with CDI to form an active intermediate, which is then attacked by amine 
to form amide. 
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The charges and sizes of the NP produced using our modified protocol was 
different from using the original protocol by Bodnar and coworkers. We could 
generate -ve CS NPs by modifying CS molecules using either TA or CA while Bodnar 
and coworkers produced it by using CA only (Table 3). This difference may be due 
to the change from acetic acid to HCI in CS solution preparation. In the orginial 
protocol, one of the carboxylic groups would react with CS molecule while another 
carboxylic group would also react with acetic acid to form amide bond. Therefore, 
all the carboxylic groups of TA were masked by either CS molecule or acetic acid and 
hence the zeta potential of CS NPs produced by adding TA was neutral. However, 
after replacing acetic acid by HCI, one of the carboxylic groups of TA would become 
available, resulting in the negative charges of CS NPs. 
In addition, the sizes of -ve CS NPs that we generated were smaller than 100 
nm whereas those produced by Bodnar and coworkers were larger than 100 nm (Fig. 
5.1). Although -ve CS NPs could be produced by using either TA or CA, the -ve CS 
NPs generated by TA were used in further experiments because its zeta potential 
was more negative (Table 3), which could interact with more +ve Bllb. 
Two methods were used to confirm the presence of Bllb in -ve CS-Bllb NPs: 
measuring the zeta potential of -ve CS-Bllb NPs and loading the re-dissolved -ve 
CS-Bllb NPs into 15% SDS-PAGE. The zeta potential of —�/f? CS-Bllb NPs was 
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significantly less negative than that of-ve CS NPs (P <0.01, Fig. 5.2). This indicated 
that Bllb was trapped in -ve CS NPs because some of the negative charges on -ve CS 
NPs was masked by the +ve Bllb, leading to less negative zeta potential. 
Additionally, a band corresponding to Bllb could be observed in 15% SDS-PAGE, after 
extensively washing the -ve CS-Bllb NPs. Hence Bllb was successfully trapped 
in -ve CS NPs. Bllb encapsulation efficiency and loading capacity in -ve CS NPs 
were 93.2% and 5.09% respectively, which were much higher than that in +ve 
CS-DTSSP Bllb NPs. The high encapsulation efficiency may be due to the strong 
and spontaneous charge-charge interaction between -ve CS NPs and +ve Bllb. 
Another group also showed that plasmid encapsulation efficiency of +ve CS NPs 
could be 100% because of electrostatic interaction (Sun et al., 2011). 
The morphologies o f -ve CS NPs and -ve CS-Bllb NPs are both spherical and 
their sizes are smaller than 100 nm, which are smaller than that of +ve CS NPs and 
+ve CS-DTSSP Bllb NPs. 
In vitro release study of -ve CS-Bllb NPs was done to investigate whether Bllb 
would be released from the NPs. About 80% of Bllb was released from the NPs 
over a period of 72 hours. It was also found that there was a burst release 
occurred initially and the release became sustainable after 8 hours. The Bllb burst 
release may be come from surface desorption of Bllb because there is a lack of 
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diffusion at front barrier to control the release of Bllb on the surface of the NPs. 
Unlike +ve CS-DTSSP Bllb NPs, the interaction between Bllb and -ve CS NPs was 
charge-charge interaction, which is weaker than covalent linkage, so Bllb from the 
interior of the NPs could still be released up to 72 hours and tend to be still releasing 
after 72 hours. Since Bllb could be released from the NPs and Bllb alone can 
permeate through cell membrane without the help of the NPs, this provides a way 
of delivering Bllb to get into the cells by releasing Bllb outside the cells after 
localizing in tumor tissues by EPR effect. 
This mode of release can be commonly found in other NPs drugs, for example 
5-Fluorouracil loaded fibrinogen NPs (5-FU-FNPs) and TNF-related apoptosis 
inducing ligand (TRAIL) loaded PEG-g-heparin/poly-L-lysine NPs (TRAIL-PEG-NPs) 
(Urn et al" 2011; Rejinold et al., 2011). In the case of TRAIL-PEG-NPs, the 
interaction between the drug and the NPs was also electrostatic interaction. Both 
NPs drugs also had moderate initial burst release followed by continuous release till 
the end of experiment, which is similar to the mode of release of -ve CS-Bllb NPs. 
-ve CS-Bllb NPs localization study was performed to examine whether the NPs 
can get into the HeLa and J774A.1 cells, -ve CS-Cy5-Bllb NPs, which has similar 
zeta potential to -ve CS-Bllb NPs, was generated to observe its localization (Table 3). 
As shown in Fig. 5.5, although the NPs could get into both types of cells, not all HeLa 
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cells could pick up the NPs while J774A.1 could. Since J774A.1 is a mouse 
monocyte-macrophage tumor, which has a more active endocytosis process than 
other cells, it is reasonable that nearly all J774A.1 could pick up the NPs. This 
showed that active uptake facilitates the cell entry of nanoparticles.. 
The toxicities of -ve CS NPs and -ve CS-Bllb NPs on J774A.1 and HeLa cells 
have also been studied, -ve CS NPs was found to be non-toxic to both types of 
cells at concentration at 18.90 mg/ml and the IC50 of-ve CS-Bllb NPs on J774A.1 and 
HeLa cells were 2.10 mg/ml and 9.06 mg/ml respectively. 
Various cells having different rate of endocytosis explains why the IC50 of the 
NPs are not the same in J774A.1 and HeLa cells. There are two main ways for Bllb 
getting into the cells: the first one is cell entry of NPs through endocytosis, the 
second one is the release of Bllb from the NPs outside the cells and then Bllb gets 
into the cells by interacting with the negatively charged membrane proteins. As 
shown in Fig. 5.3, not 100% of Bllb would be released from the NPs over the period 
of 72 hours. Therefore both two ways mentioned above should help delivering 
Bllb into the cells and hence contribute to the toxicity. Since the IC50 of free Bllb 
on both cells are similar, the rate of free Bllb getting into the cells should also be 
similar too (Fig. 4.5A). Thus, the rate of whole -ve CS-Bllb NPs getting into the 
cells by endocytosis is the primary factor affecting the toxicity of the NPs. As 
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shown in Fig. 5.5, all J774A.1 could take up the NPs while HeLa could not. This may 
explain why the toxicity of-ve CS-Bllb NPs on J774A.1 is higher than on HeLa. 
To determine whether -ve CS-Bllb NPs is less toxic than free Bllb, IC50 of the 
NPs on HeLa and J774A.1 were again converted to the concentration of Bllb for 
comparison. The IC50 of the NPs in HeLa and J774A.1 were 460.24 ng/ml (179.77 
|iM) and 106.68 pig/ml (41.67 pM) respectively. When comparing the IC50 of NPs 
with that of free Bllb, the toxicities of the NPs in HeLa was around 8-fold lower 
whereas in J774A.1 was 2-fold lower than that of the free Bllb. It is reasonable 
that both +ve CS-DTSSP Bllb NPs and -ve CS-Bllb NPs have lower toxicity than free 
Bllb because not 100% Bllb could be released from the NPs (Fig. 4.4 and 5.3) and 
not all the NPs could enter the cells (Fig. 5.4). However, toxicity differences 
between -ve CS-Bllb NPs and free Bllb were smaller than that between +ve 
CS-DTSSP Bllb NPs and free Bllb. Since the release of Bllb from +ve CS-DTSSP Bllb 
NPs mainly relies on endocytosis and on cleaving the disulfide bonds by the thiol 
reductase in lysosome whereas around 80% of Bllb can be released from -ve CS-Bllb 
NPs outside the cells or within the lysosome without any enzyme digestion, more 
Bllb from -ve CS-Bllb NPs could be released and enter into the cancer cells and 
hence its toxicity is much higher than +ve CS-DTSSP Bllb NPs. 
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A recent study showed that +ve and -ve CS NPs would affect the uptake of the 
NPs by cancer cells and normal cells. It showed that -ve CS NPs had lesser 
interaction and with a lower cellular uptake by normal cells, like blood cells, 
epithelial cells and endothelial cells as the surface charges of those cells are slight 
negative (Yue et al., 2011). Therefore, -ve CS NPs should have a longer half-life in 
the blood because -ve CS NPs would not be easily interact and get into normal cells 
in the blood circulation. It was also reported that -ve NPs could diffuse more 
quickly in tumor tissue because it will not interact with the negatively charged 
tumor cell surfaces and hence might deliver drugs deep into tumor tissues (Kim et 
al., 2010; Nomura et al., 1998). Although -ve CS-Bllb NPs have a lower cellular 
uptake, Bllb could be released from the NPs outside the cells and the released Bllb 
could enter into cancer cells without the help of the NPs. As a result, -ve CS-Bllb 
NPs is thought to be a better anti-cancer drug than +ve CS-DTSSP Bllb NPs as -ve 
CS-Bllb NPs has longer half-life in the blood, higher toxicity and can go deep into 
tumor tissue to release Bllb. 
The data showed that -ve CS-Bllb NPs is a potential anti-cancer drug candidate 
as it has the following advantages: 
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1. As -ve CS-Bllb NPs is bigger than 10 nm, unlike the free Bllb, it will not be easily 
removed by kidney. Hence the NPs drug can stay longer inside the body and its 
drug dosage can be reduced. 
2. Since it is smaller than 200 nm, it can localize itself around the solid tumor 
tissues and hence locally increase the anti-cancer drug (Bllb) concentration near 
the tumors by EPR effect. This can also decrease the lost of the drug by not 
delivering to normal tissues. 
3. Although some Bllb will be released from the NPs during blood circulation, Bllb 
will not cause damage to cells other than tumor cells as it has been shown to be 
non-toxic to normal cells including red blood cells (Lee et al., 2008). Similarly, 
after the NPs have reached the tumor tissue, Bllb released from the NPs outside 
the tumor cells will not kill the neighboring normal tissues, leading to less 
side-effects. 
4. As free Bllb can get into the cells without the help of NPs by interacting with the 
negatively charged membrane proteins of tumor cells, so -ve CS-Bllb NPs will 
still be toxic to those tumor cells with normal endocytosis rate by releasing Bllb 
from the NPs outside the cells. 
To summarize, -ve CS-Bllb NPs was successfully generated with high 
encapsulation efficiency, small size and sustainable release of Bllb. Although its 
94 
toxicities were about 2 to 8 fold lower than free Bllb, -ve CS NPs can help 
concentrating the drug to tumor tissues by EPR effect and can protect Bllb from 
renal cleara门 
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Chapter 6 一 Conclusion and future work 
To conclude, Luffin P I was successfully cloned, expressed and purified and its 
solution structure had also been solved. From the structural analysis, Luffin P I is 
unlikely to form homodimer, therefore the active site for N-glycosidase activity was 
not formed by this as suggested by previous study. In addition, we have shown 
that Luffin P I does not have any N-glycosidase activity as reported in other studies. 
The N-glycosidase activity of Luffin P I shown by Li and coworkers may be due to 
contamination when purifying Luffin P I from the seed. On the other hand, 
hlL2-Luffin P I immunotoxin was shown to exhibit potent inhibitory activity on T-cell 
proliferation in vitro (Wang et al., 2010). This may imply that Luffin P I may have 
other unknown mechanisms to inhibit protein synthesis. 
On the other hand, Bllb was successfully trapped into both +ve and -ve CS NPs 
to form +ve CS-DTSSP Bllb NPs and -ve CS-Bllb NPs respectively. From the data, 
-ve CS-Bllb NPs will be a better anti-cancer drug than +ve CS-DTSSP Bllb NPs because 
it has a higher encapsulation efficiency and loading capacity, toxicity and releasing 
rate. Although the toxicity of-ve CS-Bllb NPs is slightly lower than that of free Bllb, 
it has more advantages over free Bllb. For instance, -ve CS-Bllb NPs can localize 
itself in tumor tissue by EPR effect and will not be removed by kidney easily in 
principle, which can lower the drug dosage. Moreover, -ve CS-Bllb NPs should 
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have less side effect to human beings as CS has been proven to be safe and 
biodegradable, while Bllb will not attack normal cells, like red blood cells. As a 
result, -ve CS-Bllb NPs is a potential anti-cancer candidate drug for development. 
In the future, the toxicity of -ve CS-Bllb NPs to normal mice will be examined 
to ensure the NPs is non-toxic to animal. Then the anti-cancer activity of -ve 
CS-Bllb NPs to mice with cancer inoculation will also be tested. Finally； the 
distribution of the NPs inside the cancer mice will be studied by 
fluorescent丨y-labeled -ve CS-Bllb NPs to find out whether the NPs can successfully 
be concentrated into the tumor tissue by EPR effect. 
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